Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Rhea-AI Summary
Atossa Therapeutics (NASDAQ: ATOS) announced on January 21, 2026 that Founder and CEO Steven Quay, M.D., Ph.D. was named one of The Top 50 Healthcare Technology CEOs of 2025 by The Healthcare Technology Report. The recognition cites his leadership advancing Atossa's lead therapy, (Z)-endoxifen, across multiple Phase 2 trials and its optimization as a SERM/D with added PKCβ1 inhibition to provide consistent systemic exposure independent of CYP2D6 metabolism.
The company is also exploring (Z)-endoxifen for Duchenne Muscular Dystrophy and highlights a people-centered, innovation-driven culture under Dr. Quay.
Positive
- None.
Negative
- None.
Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology
Dr. Quay earned this recognition for his leadership in advancing innovative biotechnology solutions and building a high-performing, people-centered organization. As a physician-scientist and entrepreneur, he has guided the development of (Z)-endoxifen, Atossa's lead precision-engineered endocrine therapy, across multiple Phase 2 clinical trials and throughout the full breast cancer treatment continuum. Under his direction, the therapy has been optimized as a potent selective estrogen receptor modulator/degrader (SERM/D) with additional PKCβ1 inhibition, designed to provide consistent systemic exposure independent of CYP2D6 metabolism. The Company is also exploring the application of (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD).
"This recognition reflects our belief that meaningful innovation happens when scientific rigor, strategic discipline, and a commitment to people come together," said Dr. Quay. "At Atossa, we are focused on developing precision-based therapies while fostering a culture that empowers our team to deliver lasting impact for patients."
The Healthcare Technology Report's Top 50 Healthcare Technology CEOs awards recognize executives whose ability to drive innovation, lead through change, and translate science into real-world healthcare solutions has positioned their organizations at the forefront of healthcare technology and life sciences advancement.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-Endoxifen, is currently in development across several clinical settings. Atossa's strategy emphasizes disciplined capital allocation, focusing resources on programs and data packages that can enable future regulatory submissions and potential commercialization. More information is available at https://atossatherapeutics.com.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to, our expectations regarding the Company's development and regulatory strategy and related milestones, the potential indications that the Company may pursue for (Z)-Endoxifen, the potential for (Z)-Endoxifen to receive regulatory approval and the timing thereof, and the potential market and growth opportunities for the Company. Words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: our ability to successfully execute our strategy to shorten our clinical development timelines and pursue a metastatic breast cancer indication, DMD indication or other indications for our lead program, (Z)-Endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to regain and maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa's filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-founder-and-ceo-steven-quay-md-phd-named-one-of-the-top-50-healthcare-technology-ceos-of-2025-302666789.html
SOURCE Atossa Therapeutics Inc
FAQ
What recognition did Atossa Therapeutics CEO Steven Quay receive on January 21, 2026?
How does the award relate to Atossa Therapeutics' lead therapy (Z)-endoxifen (ATOS)?
What clinical stage is Atossa Therapeutics' (Z)-endoxifen as of January 21, 2026?
Does Atossa plan to explore other indications for (Z)-endoxifen beyond oncology?
What features of (Z)-endoxifen did Atossa emphasize in the announcement for investors following the award?
